Interest in health policies related to drug pricing has spiked in recent times. While remarkable research discoveries have positively escalated the pharmaceutical industry with release of more novel drugs, the question on how drugs should be priced is continually resurfacing. How are high drug costs justified when they become financially inaccessible to many patients, and what measures are being put in place to address these access gaps?
Host Frank Russomano welcomes Andrew Rosenberg J.D. of the CME Coalition and Thomas Sullivan, President of Rockpointe Corporation and editor of Policy and Medicine, to discuss recent developments in drug pricing.